74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Day One Biopharmaceuticals Inc
Closed
SectorHealthcare
21.47 0.05
Overview
Share price change
24h
Min
21.46
Max
21.47
Income | -1.6M -21M |
|---|---|
Sales | 14M 54M |
Profit margin | -39.611 |
Employees | 178 |
EBITDA | -3.8M -23M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -2.84% downside |
Next Earnings | 5 May 2026 |
|---|
Market Cap | 1B 2.2B |
|---|---|
Previous open | 21.42 |
Previous close | 21.47 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Day One Biopharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Day One Biopharmaceuticals Inc Forecast
Price Target
By TipRanks
-2.84% downside
12 Months Forecast
Average 20.86 USD -2.84%
High 21.5 USD
Low 17 USD
Based on 9 Wall Street analysts offering 12 month price targets forDay One Biopharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Live chat